Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu1, Robert H Blum1, Ryan Bjordahl2

  • 1Department of Medicine, University of California, San Diego, La Jolla, CA.

Blood
|December 20, 2019
PubMed
Summary

Engineered natural killer (NK) cells with a modified CD16a receptor (hnCD16-iNK) show enhanced antibody-dependent cellular cytotoxicity (ADCC) against tumors. These cells offer a promising off-the-shelf therapy for refractory hematologic malignancies and solid tumors.